The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Adenosine for Paroxysmal Supraventricular Tachycardia: Dose Ranging and Comparison with Verapamil: Assessment in Placebo-Controlled, Multicenter Trials

John P. DiMarco, MD, PhD; William Miles, MD; Masood Akhtar, MD; Simon Milstein, MD; Arjun D. Sharma, MD; Edward Platia, MD; Brian McGovern, MD; Melvin M. Scheinman, MD; and William C. Govier, MD, PhD
[+] Article, Author, and Disclosure Information

Grant Support: In part by a grant from Medco Research, Los Angeles, California.

Requests for Reprints: John P. DiMarco, MD, PhD, Cardiology Division, Box 158, University of Virginia Health Sciences Center, Charlottesville, VA 22908.

Current Author Addresses: Dr. DiMarco: Cardiology Division, Box 158, University of Virginia Health Sciences Center, Charlottesville, VA 22908.

Dr. Miles: Krannert Institute of Cardiology, 1001 West 10th Street, Indianapolis, IN 46202.

Dr. Akhtar: Mount Sinai Medical Center, University of Wisconsin School of Medicine, 950 North 12th Street, Milwaukee, WI 53233.

Dr. Milstein: University of Minnesota Hospital, Box 508, Minneapolis, MN 55455.

Dr. Sharma: 3941 J Street, Suite 260, Sacramento, CA 95819.

Dr. Platia: Washington Hospital Center, 110 Irving Street, NW, NA1045, Washington, D.C. 20010.

Dr. McGovern: Massachusetts General Hospital, Cardiac Unit, Boston, MA 02114.

Dr. Scheinman: University of California, San Francisco, Medical Center, Room 312, Moffitt Hospital, Box 0214, San Francisco, CA 94143.

Dr. Govier: Medco Research, Inc., 8744 Beverly Boulevard, Suite 404, Los Angeles, CA 90048.

The Adenosine for PSVT Study Group

© 1990 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1990;113(2):104-110. doi:10.7326/0003-4819-113-2-104
Text Size: A A A

Objective: To assess the safety and efficacy of intravenous adenosine in terminating acute episodes of paroxysmal supraventricular tachycardia.

Design: Two prospective, double-blind, randomized, placebo-controlled trials to evaluate dose response in patients receiving adenosine and to compare the effects of adenosine with those of verapamil.

Patients: A total of 359 patients with a tachycardia electrocardiographically consistent with paroxysmal supraventricular tachycardia were entered into the two protocols. Patients subsequently found to have arrhythmias other than paroxysmal supraventricular tachycardia were excluded from the efficacy analysis.

Interventions: The first protocol compared sequential intravenous bolus doses of 3, 6, 9, and 12 mg of adenosine to equal volumes of saline. In the second protocol, patients received either 6 mg and, if necessary, 12 mg of adenosine or 5 mg and, if necessary, 7.5 mg of verapamil.

Measurements and Main Results: When data are expressed in terms of cumulative response in eligible patients, intravenous adenosine terminated acute episodes of paroxysmal supraventricular tachycardia in 35.2%, 62.3%, 80.2%, and 91.4% of patients who received maximum doses of 3, 6, 9, and 12 mg, respectively, in a four-dose sequence, whereas 8.9%, 10.7%, 14.3%, and 16.1% of patients responded to four sequential placebo doses (P < 0.0001). In the second trial, cumulative response rates after 6 mg followed, if necessary, by 12 mg of adenosine were 57.4% and 93.4%, and after 5 mg followed, if necessary, by 7.5 mg of verapamil were 81.3% and 91.4%. The average time after injection to termination of tachycardia by adenosine was 30 seconds. Adenosine caused adverse effects in 36% of patients, but they lasted less than 1 minute and were usually mild.

Conclusions: Adenosine in graded doses up to 12 mg rapidly and effectively terminates acute episodes of paroxysmal supraventricular tachycardia in which the atrioventricular node is an integral part of the re-entrant circuit. The overall efficacy of adenosine is similar to that of verapamil, but its onset of action is more rapid. Adverse reactions to adenosine are common but are minor and brief.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.